The addition of nivolumab to ipilimumab conferred a long-term OS benefit for patients with advanced melanoma, according to study results presented at ESMO Congress.Final results of the randomized ...

After the approval of immune checkpoint inhibitors, overall survival among US patients with advanced-stage cancer improved, but disparities between uninsured and privately insured widened.

Nivolumab plus ipilimumab was also associated with a significant improvement in the median duration of response (30.4 months [95% CI, 21.2-not evaluable] vs 12.9 months ...

Median PFS with nivolumab + ipilimumab vs nivolumab monotherapy was not reached vs 39.3 months, respectively (HR, 0.62), and the overall response rates were 71% and 58%, respectively.

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

The median overall survival (OS) was 52.7 months with nivolumab-ipilimumab and 37.8 months with sunitinib (HR, 0.72; 95% CI 0.62-0.83). The estimated 90-month OS rates were 35.1% and 24.9% ...

Following concurrent chemoradiation for unresectable stage III non-small cell lung cancer, both nivolumab alone and nivolumab and ipilimumab combined demonstrated improved 18- month progression ...

Panelists discuss treatment considerations for metastatic melanoma with high tumor burden, highlighting the preference for immune checkpoint combinations like nivolumab with relatlimab for durable ...

A small randomized trial compared single-agent ipilimumab and combination of ipilimumab and nivolumab after anti-PD-1 failure. The results showed a 16% response rate with ipilimumab and a 12-month ...

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy in Patients with Microsatellite ...

Sandoz has signed a global collaboration agreement with Shanghai Henlius Biotech to commercialize a biosimilar of oncology therapy, ipilimumab (Bristol-Myers Squibb’s Yervoy). The agreement is ...

In combination with ipilimumab, nivolumab is indicated for the treatment of melanoma, malignant pleural mesothelioma, renal cell carcinoma, certain types of colorectal cancer, esophageal cancer ...